Acute Heart Failure (AHF) Therapeutics
Market - Size, Share, Outlook, and
Opportunity Analysis 2018–2026
Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump
enough blood through the heart to meet body’ optimal blood and oxygen level. Congestive heart
failure is type of heart failure which requires timely medical attention. Moreover, distinguish
between acute and chronic heart failure is important from a clinical standpoint, on which further
medication depends. For this, N terminal proB-type natriuretic peptide levels are used for
distinguishing acute versus chronic left ventricular dysfunction. An elevated levels of natriuretic
peptide were present in patients with acute heart failure compared to those with chronic heart failure
patient.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1910
Heart failure symptoms vary widely from person to person, depending on types of heart failure
patient. The main symptoms of heart failure are caused due to fluid accumulation or congestion and
poor blood flow to the body. Symptoms caused by fluid accumulation or congestion includes
shortness of breath, weight gain, coughing, swollen ankles, legs or abdomen, while dizziness, rapid
heart rate, and fatigue are symptoms associated with reduced blood flow to parts of the body.
Acute Heart Failure (AHF) Therapeutics Market Drivers
The global acute heart failure therapeutics market is expected to witness significant growth due to
approval of new drugs. For instance, in July 2015, Novartis received U.S. Food and Drug
Administration (FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on the treatment